U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT06986265) titled 'CKD Cachexia and Gut Microbiome' on Dec. 05, 2024.
Brief Summary: Cachexia is common in patients with chronic kidney disease (CKD) and is associated with increased morbidity and mortality. Cachexia is a complex syndrome, in which inflammation and retention of uremic toxins are two main contributing factors. In this context, the role of the gut microbiome in CKD cachexia and the potential benefit of increasing the dialysis dose have been poorly explored. Here the investigators propose to study the links between cachexia and the gut microbiome, in association with inflammation and uremic toxins, in dialysis.
The specific objectives ar...